| Bioactivity | MAO-B-IN-20 (Compound C14) is a potent MAO-B inhibitor with an IC50 of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson's disease[1]. |
| Invitro | MAO-B-IN-20 (Compound C14) 与 MAO-B 的活性位点结合，与 Safinamide (HY-70057) 具有相似的结合模式[1]。 |
| In Vivo | MAO-B-IN-20 (Compound C14; 5 mg/kg; i.v.) 在 15 分钟内迅速被吸收并穿越血脑屏障，60 分钟内在血浆和脑中达到 Cmax。MAO-B-IN-20 在 60 分钟内表现出适当的脑浆比为 16.20，并且在脑中具有高浓度 (8753 ng/g)[1]。MAO-B-IN-20 (0.08-1.28 mg/kg; i.p.; once) 以剂量依赖的方式显著抑制小鼠脑中的 MAO-B 活性[1]。MAO-B-IN-20 (0.3-3 mg/kg; i.p.; once) 在 MPTP（HY-15608） 诱导的小鼠模型中显示出对多巴胺缺陷的潜在效果，并且显著增加了纹状体中的多巴胺浓度[1]。Pharmacokinetic profile of MAO-B-IN-20 (Compound C14) in SD ratsa[1] Compound |
| Name | MAO-B-IN-20 |
| Formula | C20H18F2N2O2 |
| Molar Mass | 356.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yi C, et al. Design, synthesis and evaluation of novel monoamine oxidase B (MAO-B) inhibitors with improved pharmacokinetic properties for Parkinson's disease. Eur J Med Chem. 2023 Apr 5;252:115308. |